Insulin glulisine for continuous subcutaneous insulin infusion in pediatric type 1 diabetes

We evaluated the efficacy and safety of insulin glulisine ( GLU ) used for continuous s.c. insulin infusion ( CSII ) in 20 children with type 1 diabetes after 1 year of GLU treatment. There were no significant differences in mean plasma glucose before breakfast and before dinner between before and after using GLU , but the levels after breakfast and after dinner significantly improved, from 192.5 ± 31.7 to 162.0 ± 27.3 mg/dL for breakfast, and from 191.1 ± 33.3 to 161.1 ± 24.5 mg/dL for dinner ( P  <   0.01). Mean hemoglobin A1c significantly decreased (from 8.0 ± 0.8 to 7.7 ± 0.8%, P  <   0.05), and the mean frequency of hypoglycemia significantly reduced after using GLU (from 8.3 ± 4.9 to 6.0 ± 3.4/month, P  <   0.05). In conclusion, the use of GLU rather than other rapid‐acting analogues for CSII might be an effective treatment option in children with type 1 diabetes.